Needham & Company LLC Reiterates “Buy” Rating for AtriCure (NASDAQ:ATRC)
AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports. They presently have a $51.00 target price on the medical device company’s stock. Needham & Company LLC’s price target would suggest a potential upside of 60.23% […]
AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports. They presently have a $51.00 target price on the medical device company’s stock. Needham & Company LLC’s price target would suggest a potential upside of 60.23% […]
